‏Chitosan–Manganese Oxide Nanocomposites in Cancer Therapy: Responsive Drug Delivery and Tumor Microenvironment

‏Chitosan–Manganese Oxide Nanocomposites in Cancer Therapy: Responsive Drug Delivery and Tumor Microenvironment

Motahareh Nazari1 Neda Attaran2 Mitra Naeimi3

1) ‏Department of Biomedical Engineering, Faculty of Medical Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2) ‏Department of Medical Nanotechnology, Faculty of Medical Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, Iran.
3) Department of Biomedical Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran

IOI Code : ABEB-ACAFDA
Publication : 4th International Conference on Recent Advances in Engineering, Innovation and Technology - Belgium(eitconf.com)
Abstract :
    ‏The heterogeneity of the tumor microenvironment (TME), limitations in drug delivery, and therapeutic resistance have necessitated the development of nanosystems capable of locally modulating biological conditions. Chitosan–manganese oxide nanocomposites (CS–MnOx), combining the structural tunability and pH responsiveness of chitosan with the redox reactivity of manganese oxides, provide a promising platform for drug delivery. This review critically examines the relationships among nanocomposite architecture, microenvironmental responsiveness, drug release, and therapeutic mechanisms based on preclinical evidence. The effects of chitosan molecular characteristics, manganese oxidation states, porosity, and surface modifications on biological stability and drug-release kinetics are analyzed. In MnO₂-based systems, chitosan protonation and transformation of the inorganic component can coordinate cargo release with therapeutic activation. Glutathione depletion, oxygen generation, and Fenton-like reactions, depending on the formulation and availability of relevant stimuli, enable the integration of chemotherapy with chemodynamic, photodynamic, and photothermal therapies. Furthermore, Mn²⁺ formation offers potential applications in imaging and immune modulation. Nevertheless, the integration of multiple functionalities does not, by itself, establish therapeutic selectivity or synergy. Spatiotemporal heterogeneity, protein corona formation, off-target uptake, the biological fate of manganese, and manufacturing reproducibility remain major barriers to clinical translation. Quantitative determination of response thresholds, rigorous validation of therapeutic synergy, long-term assessment of safety and clearance, and alignment of formulations with microenvironmental biomarkers, with particular emphasis on biological limitations and the requirements for robust translational evaluation, provide a framework for the mechanism-guided development of these nanoplatforms in precision cancer nanomedicine.

Keywords : ‏tumor microenvironment modulation redox homeostasis regulation stimuli responsive drug delivery combination cancer therapy chitosan manganese oxide nanocomposites